Permethrin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Permethrin
Permethrin: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Permethrin, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 6 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| mite infestation |
| norwegian scabies |
| pediculus humanus capitis infestation |
| pediculus humanus corporis infestation |
| pthirus pubis infestation |
| scabies |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 3054R | Lyclear | Cream 50 mg per g, 30 g | Valid |
Safety Considerations
- Knowledge-graph contraindication signal: the TxGNN knowledge graph lists bronchial disease as a contraindication. This is a graph-derived association, not label text, and should be verified against the product information.
Please refer to the TGA-approved Product Information (PI) for full warnings, contraindications and drug interaction information. No drug interactions were found in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.